27 research outputs found
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer
Objective: PDAC patients who undergo surgical resection and receive effective chemotherapy have the best chance of long-term survival. Unfortunately, we lack predictive biomarkers to guide optimal systemic treatment. Ex-vivo generation of PDO for pharmacotyping may serve as predictive biomarkers in PDAC. The goal of the current study was to demonstrate the clinical feasibility of a PDO-guided precision medicine framework of care. Methods: PDO cultures were established from surgical specimens and endoscopic biopsies, expanded in Matrigel, and used for high-throughput drug testing (pharmacotyping). Efficacy of standard-of-care chemotherapeutics was assessed by measuring cell viability after drug exposure. Results: A framework for rapid pharmacotyping of PDOs was established across a multi-institutional consortium of academic medical centers. Specimens obtained remotely and shipped to a central biorepository maintain viability and allowed generation of PDOs with 77% success. Early cultures maintain the clonal heterogeneity seen in PDAC with similar phenotypes (cystic-solid). Late cultures exhibit a dominant clone with a pharmacotyping profile similar to early passages. The biomass required for accurate pharmacotyping can be minimized by leveraging a high-throughput technology. Twenty-nine cultures were pharmacotyped to derive a population distribution of chemotherapeutic sensitivity at our center. Pharmacotyping rapidly-expanded PDOs was completed in a median of 48 (range 18-102) days. Conclusions: Rapid development of PDOs from patients undergoing surgery for PDAC is eminently feasible within the perioperative recovery period, enabling the potential for pharmacotyping to guide postoperative adjuvant chemotherapeutic selection. Studies validating PDOs as a promising predictive biomarker are ongoing.Peer reviewe
Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo
Pancreatic cancer is the fourth leading cause of cancer related deaths in America. Monoclonal antibodies are a viable treatment option for inhibiting cancer growth. Tumor specific drug delivery could be achieved utilizing these monoclonal antibodies as targeting agents. This type of designer therapeutic is evolving and with the use of gold nanoparticles it is a promising approach to selectively deliver chemotherapeutics to malignant cells. Gold nanoparticles (GNPs) are showing extreme promise in current medicinal research. GNPs have been shown to non-invasively kill tumor cells by hyperthermia using radiofrequency. They have also been implemented as early detection agents due to their unique X-ray contrast properties; success was revealed with clear delineation of blood capillaries in a preclinical model by CT (computer tomography). The fundamental parameters for intelligent design of nanoconjugates are on the forefront. The goal of this study is to define the necessary design parameters to successfully target pancreatic cancer cells.The nanoconjugates described in this study were characterized with various physico-chemical techniques. We demonstrate that the number of cetuximab molecules (targeting agent) on a GNP, the hydrodynamic size of the nanoconjugates, available reactive surface area and the ability of the nanoconjugates to sequester EGFR (epidermal growth factor receptor), all play critical roles in effectively targeting tumor cells in vitro and in vivo in an orthotopic model of pancreatic cancer.Our results suggest the specific targeting of tumor cells depends on a number of crucial components 1) targeting agent to nanoparticle ratio 2) availability of reactive surface area on the nanoparticle 3) ability of the nanoconjugate to bind the target and 4) hydrodynamic diameter of the nanoconjugate. We believe this study will help define the design parameters for formulating better strategies for specifically targeting tumors with nanoparticle conjugates
Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
Undoubtedly ovarian cancer is a vexing, incurable disease for patients with
recurrent cancer and therapeutic options are limited. Although the polycomb
group gene, Bmi-1 that regulates the self-renewal of normal
stem and progenitor cells has been implicated in the pathogenesis of many human
malignancies, yet a role for Bmi-1 in influencing chemotherapy response has not
been addressed before. Here we demonstrate that silencing Bmi-1 reduces
intracellular GSH levels and thereby sensitizes chemoresistant ovarian cancer
cells to chemotherapeutics such as cisplatin. By exacerbating ROS production in
response to cisplatin, Bmi-1 silencing activates the DNA damage response
pathway, caspases and cleaves PARP resulting in the induction apoptosis in
ovarian cancer cells. In an in vivo orthotopic mouse model of
chemoresistant ovarian cancer, knockdown of Bmi-1 by nanoliposomal delivery
significantly inhibits tumor growth. While cisplatin monotherapy was inactive,
combination of Bmi-1 silencing along with cisplatin almost completely abrogated
ovarian tumor growth. Collectively these findings establish Bmi-1 as an
important new target for therapy in chemoresistant ovarian cancer
Recommended from our members
Neuropsychiatric symptoms in untreated Parkinson’s disease
Neuropsychiatric and cognitive symptoms are common in Parkinson’s disease (PD) and may precede and exceed motor symptoms as major factors impacting disease course and quality of life. Neuropsychiatric symptoms (NPS) in PD are various and are attributed to pathologic changes within multiple brain regions, to psychological stress, and to adverse effects of dopamine replacement therapy. Sleep disorders and mood symptoms such as apathy, depression, and anxiety may antedate the development of motor symptoms by years, while other NPS such as impulse control disorders, psychosis, and cognitive impairment are more common in later stages of the disease. Few studies report on NPS in the early, untreated phase of PD. We reviewed the current literature on NPS in PD with a focus on the early, drug-naive stages of PD. Among these early disease stages, premotor and early motor phases were separately addressed in our review, highlighting the underlying pathophysiological mechanisms as well as epidemiological characteristics, clinical features, risk factors, and available techniques of clinical assessment
Cell adhesion molecules in stromal corneal dystrophies
The aim of the present study was to
investigate the expression pattern of different cell
adhesion molecules in corneal stromal dystrophies.
Fifteen corneal buttons from patients diagnosed with
three different types of stromal corneal dystrophies and
healthy corneas were investigated. Paraffin embedded
sections were stained immunohistochemically with
monoclonal antibodies against human intercellular
adhesion molecule-1 (ICAM-1), endothelial selectin (Eselectin)
and endothelial cadherin (E-cadherin) using the
avidin-biotin-peroxidase-complex technique. The
sections were compared to normal eye bank controls.
In corneas from granular dystrophy patients ICAM-1
was expressed focally in epithelial cells and in
keratocytes, and expressed diffusely in endothelial cells.
In corneas from macular dystrophy patients diffuse
epithelial staining was observed and the stromal and
endothelial expression was found to be similar to that of
granular dystrophy. In lattice dystrophy, only the
epithelial cells and endothelium were intensively
positive for ICAM-1. E-selectin was not present on any layer of the corneal specimens. E-cadherin was observed
only in the epithelium of all three types of corneal
dystrophies. Normal corneas did not express any of the
investigated adhesion molecules.
We found different expression patterns of adhesion
molecules in corneas from stromal dystrophies. Our
results suggest that adhesion molecules may be involved
in the pathogenesis of corneal stromal dystrophies
A computer-assisted microscopic analysis of bone tissue developed inside a polyactive polymer implanted into an equine articular surface
One of the most promising applications for the restoration of small or moderately sized focal articular lesions is mosaicplasty (MP). Although recurrent hemarthrosis is a rare complication after MP, recently, various strategies have been designed to find an effective filling material to prevent postoperative bleeding from the donor site. The porous biodegradable polymer Polyactive (PA; a polyethylene glycol terephthalate - polybutylene terephthalate copolymer) represents a promising solution in this respect. A histological evaluation of the longterm PA-filled donor sites obtained from 10 experimental horses was performed. In this study, attention was primarily focused on the bone tissue developed in the plug. A computer-assisted image analysis and quantitative polarized light microscopic measurements of decalcified, longitudinally sectioned, dimethylmethylene blue (DMMB)- and picrosirius red (PS) stained sections revealed that the coverage area of the bone trabecules in the PA-filled donor tunnels was substantially (25%) enlarged compared to the neighboring cancellous bone. For this quantification, identical ROIs (regions of interest) were used and compared. The birefringence retardation values were also measured with a polarized light microscope using monochromatic light. Identical retardation values could be recorded from the bone trabeculae developed in the PA and in the neighboring bone, which indicates that the collagen orientation pattern does not differ significantly among these bone trabecules. Based on our new data, we speculate that PA promotes bone formation, and some of the currently identified degradation products of PA may enhance osteo-conduction and osteoinduction inside the donor cana
Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients
Data on longer right to left ventricular activation delay (RV-LV AD) predicting clinical outcome after cardiac resynchronization therapy (CRT) by left bundle branch block (LBBB) are limited. We aimed to evaluate the impact of RV-LV AD on N-terminal pro-B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), and clinical outcome in patients implanted with CRT, stratified by LBBB at baseline
Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients
AIMS: Data on longer right to left ventricular activation delay (RV-LV AD) predicting clinical outcome after cardiac resynchronization therapy (CRT) by left bundle branch block (LBBB) are limited. We aimed to evaluate the impact of RV-LV AD on N-terminal pro–B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), and clinical outcome in patients implanted with CRT, stratified by LBBB at baseline. METHODS AND RESULTS: Heart failure (HF) patients undergoing CRT implantation with EF ≤ 35% and QRS ≥ 120 ms were evaluated based on their RV-LV AD at implantation. Baseline and 6-month clinical parameters, EF, and NT-proBNP values were assessed. The primary endpoint was HF or death, the secondary endpoint was all-cause mortality. A total of 125 patients with CRT were studied, 62% had LBBB. During the median follow-up of 2.2 years, 44 (35%) patients had HF/death, 36 (29%) patients died. Patients with RV-LV AD ≥ 86 ms (lower quartile) had significantly lower risk of HF/death [hazard ratio (HR): 0.44; 95% confidence interval (95% CI): 0.23–0.82; P = 0.001] and all-cause mortality (HR: 0.48; 95% CI: 0.23–1.00; P = 0.05), compared with those with RV-LV AD < 86 ms. Patients with RV-LV AD ≥ 86 ms and LBBB showed the greatest improvement in EF (28–36%; P<0.001), NT-proBNP (2771–1216 ng/mL; P < 0.001), and they had better HF-free survival (HR: 0.23, 95% CI: 0.11–0.49, P < 0.001) and overall survival (HR: 0.35, 95% CI: 0.16–0.75; P = 0.007). There was no difference in outcome by RV-LV AD in non-LBBB patients. CONCLUSION: Left bundle branch block patients with longer RV-LV activation delay at CRT implantation had greater improvement in NT-proBNP, EF, and significantly better clinical outcome
Immunohistochemistry Analysis of Tumors from the PBS and ACG44 groups.
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057522#pone-0057522-g004" target="_blank">Figure 4A and 4B</a> show representative images of H&E and Ki-67 stained tumor tissues, respectively, from the PBS treated group whereas <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057522#pone-0057522-g004" target="_blank">Figure 4C and 4D</a> show images of H&E and Ki-67 staining of tumor tissue from the ACG44 treated group. All images were taken with 20× magnification. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057522#pone-0057522-g004" target="_blank">Figure 4E</a> is quantification of the Ki-67 positive proliferative nuclei shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057522#pone-0057522-g004" target="_blank">Figures 4B and 4D</a>. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057522#pone-0057522-g004" target="_blank">Figure 4F</a> is a tumor image of Ki-67 staining from the ACG44 treated group, taken at 100 X to show gold accumulation (black spots) at a high magnification.</p